



ORIGINALS

Bilingual edition English/Spanish

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma

Evaluación económica y análisis de impacto presupuestario de mepolizumab en asma eosinofílica refractaria grave

Leticia García-Mochón^{1*}, Manuel David Gil-Sierra^{2,3*}, Emilio Jesús Alegre-del Rey², Catalina Alarcón de la Lastra-Romero³, Marina Sánchez-Hidalgo³

¹Andalusian School of Public Health, Granada. Spain. Biomedical Research Center at Ciber for Epidemiology and Public Health (CIBERESP by its Spanish acronym), Madrid. Spain. IBS Biomedical Research Institute, Granada. Spain. University Hospitals of Granada/University of Granada, Granada. Spain. ²Pharmacy Service, Puerto Real University Hospital, Puerto Real. Spain. ³Department of Pharmacology, School of Pharmacy, University of Seville, Seville. Spain.

*Both authors have contributed equally.

Author of correspondence

Manuel David Gil-Sierra
C/ Playa de Bolonia, 10,
11406 Jerez de la Frontera,
Cádiz, Spain.

Email:
mangilsie@yahoo.com

Received 6 February 2019;
Accepted 3 June 2019.
DOI: 10.7399/fh.11221

How to cite this paper

García-Mochón L, Gil-Sierra MD, Alegre-del Rey EJ, Alarcón de la Lastra-Romero C, Sánchez-Hidalgo M. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma. *Farm Hosp*. 2019;43(6):187-93.

Abstract

Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin E who are candidates of omalizumab and mepolizumab, as well as mepolizumab's economic impact, lead to make efficient economic studies for clinical decision making. The aim was to analyze mepolizumab's cost-efficacy and budget impact.

Method: Cost comparison and the use of mepolizumab's budgetary impact was performed, from the Spanish National Health System's perspective. Among the assessed alternatives, inhaled systemic corticosteroids, plus long acting beta agonist (β_2) and/or oral systemic corticosteroids in patients with non immunoglobulin E-mediated severe allergic asthma, and said treatment along with omalizumab in patients with immunoglobulin E mediated eosinophilic allergic asthma were included. Its efficacy was evaluated through avoided clinically relevant exacerbations. The direct costs associated with exacerbation were assessed.

Results: Mepolizumab's long run average incremental cost regarding omalizumab's is 797 euros per patient a year. Considering omalizumab's alternative discounted price, including mepolizumab for patients with immu-

Resumen

Objetivo: Mepolizumab está indicado como tratamiento adicional del asma eosinofílica refractaria grave. Las diferencias observadas en subgrupos poblacionales según recuento eosinofílico plasmático, existencia de pacientes con altos niveles de inmunoglobulina E candidatos a omalizumab y mepolizumab, e impacto económico de mepolizumab obligan a realizar estudios económicos para tomar decisiones clínicas eficientes. El objetivo fue realizar un análisis de coste/eficacia e impacto presupuestario de mepolizumab.

Método: Se realizó la comparación de costes e impacto presupuestario del uso de mepolizumab desde la perspectiva del Sistema Nacional de Salud. Las alternativas valoradas fueron corticosteroides sistémicos inhalados + agonista β_2 de larga duración y/o corticosteroides sistémicos orales en pacientes con asma alérgica grave no mediada por inmunoglobulina E, y este tratamiento junto a omalizumab en pacientes con asma eosinofílica alérgica mediada por inmunoglobulina E. La eficacia se evaluó mediante exacerbaciones clínicamente relevantes evitadas. Se valoraron los costes directos asociados a exacerbación.

Resultados: El coste incremental medio de mepolizumab respecto a omalizumab es de 797 euros por paciente y año. Considerando precio alternativo con descuento de omalizumab, incluir mepolizumab para pa-

KEYWORDS

Costs; Economic assessment; Budgetary impact; Mepolizumab; Omalizumab.

PALABRAS CLAVE

Costes; Evaluación económica; Impacto presupuestario; Mepolizumab; Omalizumab.



Los artículos publicados en esta revista se distribuyen con la licencia
Articles published in this journal are licensed with a
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
<http://creativecommons.org/licenses/by-nc-sa/4.0/>
La revista Farmacia no cobra tasas por el envío de trabajos,
ni tampoco por la publicación de sus artículos.

noglobulin E mediated eosinophilic allergic asthma would increase public spending from 2.3 to 4.6 million euros. Given omalizumab's notified price, the gradual introduction of mepolizumab in the Spanish National Health System would save 3.6 million euros in three years. For non immunoglobulin E-mediated severe asthma patients, the avoided cost/exacerbation by introducing mepolizumab is 15,085 euros, assuming a gradual market penetration of mepolizumab. In patients with ≥ 500 eosinophils/ μL , this cost decreases to 7,767 euros per avoided exacerbation with a budgetary impact of 183.2 million euros in three years with a progressive penetration of mepolizumab.

Conclusions: The cost comparison between mepolizumab and omalizumab in immunoglobulin E mediated eosinophilic asthma patients suggests a use of the lower cost drug, promoting price competition. Additionally, prioritizing its use among non immunoglobulin E-mediated severe refractory eosinophilic asthma patients and ≥ 500 eosinophils/ μL plasma level patients, would improve its efficiency as well as reducing its budgetary impact.

Introduction

It is estimated that asthma affects approximately 4.9% of adults¹. In Spain, the prevalence of patients with uncontrolled or refractory severe asthma to corticosteroids and β_2 long acting beta agonist (LABA) treatment is approximately 3.9% of asthmatics². Within this group, about 25% have eosinophilic asthma, characterized by a late onset, presence of eosinophils in bronchial biopsies and is usually associated with nasal polyps, rhinosinusitis and respiratory infections^{3,4}.

Omalizumab is a monoclonal antibody indicated in uncontrolled severe allergic asthma authorized in Spain in 2006⁵. The dosage of omalizumab is variable, ranging from a minimum of 75 mg every 4 weeks up to 600 mg every 2 weeks⁵. In 2015, mepolizumab is marketed. This monoclonal antibody is indicated as an additional treatment for adult patients with severe refractory eosinophilic asthma⁶. Mepolizumab acts by binding to interleukin 5 and preventing its interaction with the surface of eosinophils. This causes a reduction in their production and survival. The recommended dose is 100 mg every 4 weeks. Studies evaluating the dose of mepolizumab and eosinophilic response show a similar pharmacodynamics between 100 mg and 75 mg⁷.

In the pivotal clinical trials for authorizing mepolizumab, the effect as a main variable on the frequency of exacerbations that are clinically relevant was measured^{8,9}. A clinically relevant exacerbation is an acute asthma attack requiring the use of systemic corticosteroids for at least three days and/or hospitalization and/or emergency room visits, or doubling the dose of systemic corticosteroids for at least three days in patients treated with oral corticosteroids as maintenance therapy^{8,9}. Mepolizumab has proven to be effective in reducing exacerbations and daily doses of oral systemic corticosteroids (OCS) in patients with severe eosinophilic asthma not adequately controlled with high doses of inhaled systemic corticosteroids (ICS) + LABA and/or OCS (usual treatment).

However, a higher frequency of asthma attacks is associated with a high eosinophils count (> 300 - 400 cells/ μL)^{10,11}. In the subgroup analysis of the pivotal clinical trials, it is also observed that the relative benefit is greater in patients with higher blood levels of eosinophils^{8,9}. Subgroup analysis is pre-specified and shows statistical interaction. The difference is consistent in studies^{7,12} and there is biological plausibility, as an inhibitor for eosinophils could exert a greater action, the bigger the contribution of eosinophilia is to the asthmatic process.

It should be noted that approximately 30% of diagnosed eosinophilic asthmatic patients show signs and symptoms that are consistent with the IgE-mediated persistent allergic asthma phenotype¹³, meeting omalizumab's treatment criteria. However, no evidence exists to opt for either therapy in this subpopulation¹².

Given the differences in subgroups according to eosinophils count in severe refractory eosinophilic asthma, the existence of candidates for omalizumab patients or mepolizumab, and the economic impact resulting from the use of mepolizumab, it seems crucial to conduct a study of

cientos con asma eosinofílica alérgica y mediada por inmunoglobulina E supondría incrementar el gasto público de 2,3 a 4,6 millones de euros. Teniendo en cuenta el precio notificado de omalizumab, la introducción gradual de mepolizumab en el Sistema Nacional de Salud supondría ahorrar 3,6 millones de euros en tres años. Para pacientes con asma grave no mediada por inmunoglobulina E, el coste/exacerbación evitada al añadir mepolizumab es de 15.085 euros, con un impacto presupuestario en tres años de 578,4 millones de euros, asumiendo una penetración progresiva de mepolizumab en el mercado. En los pacientes con ≥ 500 eosinófilos/ μL , este coste disminuye a 7.767 euros por exacerbación evitada, con un impacto presupuestario de 183,2 millones de euros en tres años con penetración progresiva de mepolizumab.

Conclusiones: La comparación de costes entre mepolizumab y omalizumab en pacientes con asma eosinofílica mediada por inmunoglobulina E señala como razonable utilizar el fármaco de menor coste, promoviendo competencia de precios. Asimismo, priorizar su uso en pacientes con asma eosinofílica refractaria grave no mediada por inmunoglobulina E y niveles plasmáticos ≥ 500 eosinófilos/ μL permitiría mejorar la eficiencia y disminuir el impacto presupuestario.

economic evaluation and budgetary impact that helps making efficient clinical decisions. At the time of this work, other similar action mechanism drugs to mepolizumab –reslizumab and benralizumab– were pending funding and price in Spain^{4,15}. These drugs were not compared to mepolizumab, and it is difficult to differentiate between them. The economic comparison of these therapies in the same group is not the subject of this study.

The aim of this work is to perform a cost-efficacy and budgetary impact analysis (BIA) of mepolizumab's as treatment for severe refractory eosinophilic asthma, mediated and non mediated by elevated IgE levels in adult patients who are not adequately controlled with high dose of ICS + LABA and/or OCS in Spain.

Methods

The cost-efficacy analysis and the BIA were developed from the perspective of the Spanish National Health System (NHS). Only direct costs were quantified in euros in 2018. The BIA was carried out for a period of three years (2018-2020). Analyses were performed taking into account the latest economic assessment and BIA guidelines^{6,17}.

Study population

The study population included patients over 12 years with severe refractory asthma. Adult asthmatic population estimates and the prevalence of severe refractory asthma in Spain were employed for the BIA^{1,2}. Subsequently, the percentage of patients to treatment with severe refractory asthma, diagnosed with eosinophilic asthma was calculated. Asthmatic population mediated with elevated IgE levels who is candidate for therapy with omalizumab were also calculated by using data from the Spanish National Statistics Institute¹⁸. In addition, a population subgroups BIA was performed according to plasma eosinophil count (Table 1).

Evaluated therapeutic alternatives

The cost-efficacy analysis, as well as BIA on the use of mepolizumab was performed using two different analysis according to the studied population.

In analysis 1, the analyzed population was diagnosed with eosinophilic allergic asthma and IgE mediated. In these patients, the high dose association of ICS + LABA and/or OCS along with mepolizumab was compared to the same medication associated with omalizumab.

In analysis 2, the study population was suffering from non IgE-mediated severe refractory asthma, and other alternatives to mepolizumab were not considered. Thus, the use of ICS + LABA and/or OCS with mepolizumab in high doses was assessed against high doses of ICS + LABA and/or OCS. This second analysis excludes 30% of patients with eosinophilic asthma (who were treated with omalizumab).

The evaluated mepolizumab dosage is 100 mg every 4 weeks⁷. Omalizumab is dosed based on body weight and basal IgE levels. The dose ranges from 75 mg every 4 weeks to 600 mg every 2 weeks⁵. Regarding cost analysis, an average of these values was employed (Table 1).

Measure health outcomes

The efficacy of the therapies was obtained from the Therapeutic Positioning Report on mepolizumab¹² and from the European Medicines Agency's assessment report on mepolizumab⁷. Clinical exacerbations, including those requiring hospitalization or emergency room visits and rele-

vant clinical exacerbations by population subgroups according to plasma eosinophil count were estimated (Table 1). The drug efficacy was assessed by reducing the average of clinically relevant annual exacerbations for using mepolizumab against its therapeutic alternative. Conducting a cost minimization study requires clinical equivalence evidence of the tested drugs. Comparative clinical evidence is lacking quality between mepolizumab and omalizumab that shows clinical equivalence or difference between the two therapies. Therefore, a cost minimization study could not be performed, but a cost comparison study was carried out instead in analysis 1.

Table 1. Prevalence values, efficiency and cost used in budget impact analysis

	Average value	Minimum-maximum value	Source
Asthma prevalence data (%)^a			
Population with asthma	4.9	—	European study on asthma ¹
Severe refractory asthma population	3.9	—	Quirce S, <i>et al.</i> ²
Eosinophilic candidate population	25.0	—	TPR mepolizumab ¹²
< 150 eosinophils/ μ L subgroup	23.1	—	EMA report ⁷
< 150 eosinophils/ μ L subgroup	26.1	—	EMA report ⁷
< 300 eosinophils/ μ L subgroup	20.5	—	EMA report ⁷
\geq 500 eosinophil cells/ μ L subgroup	30.4	—	EMA report ⁷
Eosinophilic asthma population and IgE-mediated, current omalizumab candidates.	30.0	—	OSMO study ¹³
Clinically relevant exacerbations rates in OCS group			
Total population with uncontrolled severe eosinophilic asthma			
Clinically relevant exacerbations	1.91	—	EMA report ⁷
Exacerbations requiring hospitalization or emergency room visits	0.26	—	EMA report ⁷
Exacerbations requiring hospitalization	0.14	—	EMA report ⁷
Population subgroups according to levels of eosinophils			
< 150 eosinophils/ μ L	1.73	—	EMA report ⁷
150 to < 300 eosinophils/ μ L	1.14	—	EMA report ⁷
300 to < 500 eosinophils/ μ L	1.64	—	EMA report ⁷
\geq 500 eosinophils/ μ L	2.49	—	EMA report ⁷
MEPO's relative risk vs OCS in clinically relevant exacerbations			
Total population with uncontrolled severe eosinophilic asthma			
Clinical exacerbations	0.51	0.42-0.62 ^b	EMA report ⁷
Exacerbations requiring hospitalization or emergency room visits	0.53	0.33-0.80 ^b	EMA report ⁷
Exacerbations requiring hospitalization	0.50	0.28-0.89 ^b	EMA report ⁷
Population subgroups according to levels of eosinophils			
< 150 eosinophils/ μ L	0.67	0.46-0.98 ^b	EMA report ⁷
150 to < 300 eosinophils/ μ L	0.72	0.47-1.10 ^b	EMA report ⁷
300 to < 500 eosinophils/ μ L	0.62	0.41-0.93 ^b	EMA report ⁷
\geq 500 eosinophils/ μ L	0.27	0.19-0.37 ^b	EMA report ⁷
Drug costs (€)			
Mepolizumab	14,118	—	BotPlus ¹⁹
Omalizumab (notified price)	14,402	—	BotPlus ¹⁹
Omalizumab (alternative discounted price)	13,321	—	—
Other related costs (€)			
Hospital's emergency care cost	153.15	122.50-183.78 ^c	AsmaCost study ²⁰
Hospital stay cost (cost/day)	407.57	326-489 ^c	AsmaCost study ²⁰
Hospital stays cost for exacerbation	3,845.43	2,028-7,860 ^d	AsmaCost study ²⁰

EMA: European Medicines Agency; MEPO: mepolizumab; OCS: oral systemic corticosteroids; TPR: Therapeutic Positioning Report.

^aCalculations have been made for the resident population in Spain. These projections were calculated in October, 2014 with the interim population as reference to January 1, 2014 (latest population figure available at the time). ^bMinimum and maximum values according to confidence interval 95% of the studies. ^cMinimum and maximum values assuming a 20% variation over the average. ^dAverage cost corresponds to an average stay of 9 days, minimum and maximum values have been calculated by assuming 5 and 12 days of admission, respectively.

Cost estimate

The cost of medication (mepolizumab and omalizumab), of relevant clinical exacerbations, of emergency room visits and for hospitalization due to asthma exacerbations were included. Treatments were evaluated by laboratory sales price of drugs according to the Catalog of Medicinal Products of the General Council of Official Colleges of Pharmacists¹⁹. In regard to omalizumab, its notified and alternative price according to the routine clinical practice was collected, with a hypothetical price discount of 7.3%. Mepolizumab matches both the notified and alternative prices (Tables 1 and 2). The cost of a clinically significant exacerbation requiring hospitalization and/or emergency care, and hospitalization cost –assuming an average stay of nine days– were extracted from AsmaCost²⁰ study, updated to euro currency in 2018. The analysis includes drugs' direct costs and hospitalization and emergency care costs, due to its impact on the definition of clinically significant exacerbation. The study does not include costs arising from hospital medication management.

This study evaluated the incremental cost and cost of treatment in the BIA analysis 1, and cost per avoided exacerbation and treatment cost in the study population in analysis 2.

Scenario analysis and uncertainty

In analysis 1, several scenarios of gradual market penetration of mepolizumab replacing omalizumab (50, 70 and 100%) were carried out, and with different prices of omalizumab –notified and alternative prices–. In analysis 2, a sensitivity study was performed in order to assess the uncertainty about the minimum and maximum values of the confidence interval, 95% of relative risks (RR) of the variables (relevant clinical exacerbation, hospitalization and emergency care), as well as hospitalization costs and emergency care (Table 1). Analyses were performed using Microsoft Excel 2016®.

Results

The estimated study population is shown in table 1.

Analysis 1. Eosinophilic allergic asthma population and IgE-mediated

A mepolizumab average incremental cost opposed to omalizumab (alternative price) was estimated to be 797 euros per patient and year, although depending on each patient and dosage of omalizumab. In table 2, BIA data is shown according to its market penetration, notified or alternative price and year for IgE mediated eosinophilic asthma patients. Considering omalizumab's alternative discounted price, the scenario where mepolizumab could be included for patients with IgE mediated eosinophilic allergic asthma would cause an increase public spending from 2.3 to 4.6 million euros, according to the year and degree of mepolizumab's market penetration. The budgetary impact in three years would bring, either an increase of 10.3 million euros with gradual market penetration, or 14 million euros in a scenario where omalizumab would completely be replaced by mepolizumab. Considering omalizumab's notified price –which is greater than the alternative price–, the gradual introduction of mepolizumab in the NHS would save 3.6 million euros over three years, while the complete replacement of omalizumab for mepolizumab could reduce about 5 million of euros of public spending.

Analysis 2. Population with non IgE-mediated severe refractory asthma

Table 3 shows the data cost per avoided exacerbation applicable to people with non IgE-mediated eosinophilic severe refractory asthma, which constitutes 70% of the susceptible population of treatment for which the therapeutic alternative considered was ICS + LABA and/or OCS. The cost per avoided exacerbation by adding mepolizumab is 15,085 euros. Patients subgroups data according to their eosinophils plasma show a cost of 7,767 euros per avoided exacerbation (≥ 500 eosinophils/ μ L patients) for the group whose basal affectation is greater.

The sensitivity study shows that the RR is a very sensitive variable to the patients subgroups' results. By taking maximum values of RR in < 500 eosinophils/ μ L subgroups, higher costs for avoided exacerbation are obtained, which are more than 100,000 additional euros opposed to the general population

Table 2. Budget impact analysis results in patients with allergic eosinophilic asthma and IgE mediated (year 2018-2020)

Year	Population (candidates)	Current situation		New situation	
		OMA cost (€)	% OMA substitution for MEPO	MEPO cost and OMA (€)	BIA (MEPO cost – OMA cost) (€)
OMA notified cost price. MEPO progressive market penetration					
2018	5,858	84,358,056	50	83,527,657	-830,399.25
2019	5,868	84,506,625	70	83,342,019	-1,162,558.96
2020	5,880	84,677,546	100	83,010,457	-1,660,798.51
2018-2020		253,542,227	–	249,880,133	-3,653,757.00
OMA notified cost price. 100% MEPO market penetration on the onset					
2018	5,858	84,358,056	100	82,697,257	-1,660,798.51
2019	5,868	84,506,625	100	82,842,902	-1,663,723.47
2020	5,880	84,677,546	100	83,010,457	-1,667,088.46
2018-2020		253,542,227	–	248,550,616	-4,991,610.00
OMA alternative price cost. MEPO progressive market penetration					
2018	5,858	78,030,116	50	80,363,687	2,333,570.40
2019	5,868	78,167,542	70	81,440,294	3,272,752.32
2020	5,880	78,325,641	100	83,010,457	4,684,816.69
2018-2020		234,523,298	–	249,880,133	10,291,140.00
OMA alternative price cost. 100% MEPO market penetration on the onset					
2018	5,858	78,030,116	100	82,697,257	4,667,140.79
2019	5,868	78,167,542	100	82,842,902	4,675,360.46
2020	5,880	78,325,641	100	83,010,457	4,684,816.69
2018-2020		234,523,298	–	248,550,616	14,027,318.00

BIA: budget impact analysis; MEPO: mepolizumab; OMA: omalizumab.

Table 3. Cost per avoided exacerbation in population with severe refractory eosinophilic asthma (applicable to non IgE-mediated asthmatic patients) in 2018

	Basal analysis (RR mean value)			Sensitivity analysis (best-case scenario, minimum RR values)		Sensitivity analysis (worst-case scenario, maximum RR values)	
	MEPO cost (€)	Avoided exacerbations	Cost/avoided exacerbation ^a (€)	Avoided exacerbations	Cost/avoided exacerbation (€)	Avoided exacerbations	Cost/avoided exacerbation (€)
Uncontrolled severe eosinophilic asthma population	14,118	0.936	15,085.0	1.100	12,744.2	0.726	19,451.6
Subgroup: < 150 eosinophils/ μ L	14,118	0.570	24,729.4	0.934	15,112.4	0.035	408,034.7
Subgroup: 150 to <300 eosinophils/ μ L	14,118	0.320	44,229.3	0.604	23,366.4	-0.114	Dominated
Subgroup: 300 to <500 eosinophils/ μ L	14,118	0.620	22,654.0	0.986	14,590.7	0.115	122,979.1
Subgroup: \geq 500 eosinophils/ μ L	14,118	1.820	7,767.0	2.017	6,999.9	1.569	8,999.8

MEPO: mepolizumab; RR: relative risk.

^aMEPO + usual therapy versus usual therapy. Usual treatment: inhaled systemic corticosteroids + long acting beta agonist (β 2) + oral systemic corticosteroids.

with uncontrolled eosinophilic asthma. In contrast, in a scenario of minimum RR values for the subgroup of patients with levels from 300 to <500 eosinophils/ μ L, mepolizumab would cost 14,591 euros per avoided exacerbation.

Table 4 provides BIA data for the non IgE-mediated refractory eosinophilic asthma population, as well as for subgroups according to plasma levels of eosinophils. The annual budgetary impact of population with non IgE-mediated eosinophilic asthma would reach 189 million euros (568.1 million over three years). If we add this amount to the result in three years of BIA for patients with IgE-mediated eosinophilic asthma (30% of the overall patients with eosinophilic asthma), and assuming a progressive market penetration of mepolizumab (10.3 million according to Table 2), a total BIA of 578.4 million euros for the population. The BIA for non IgE-mediated eosinophilic asthma population, which is divided into subgroups according to their eosinophils plasma levels (Table 4) gives us some estimates of annual 57.5 million in the subgroup with \geq 500 cells/ μ L eosinophil count –which translates into 173 m in three years–. If we add the BIA result with a progressive introduction of mepolizumab in three years for IgE-mediated eosinophilic asthma patients to the use of mepolizumab's BIA, only in people with non IgE-mediated eosinophilic asthma and \geq 500 eosinophils/ μ L levels, the BIA for all the population in three years would be 183.2 million euros.

Table 4 shows a sensitivity study on mepolizumab's budgetary impact for the subgroup of patients with \geq 500 eosinophils/ μ L. It illustrates the variations in the BIA that could occur in mepolizumab's best and worst scenario, varying costs of emergency, hospitalization and RR of clinically relevant exacerbations. It is observed that the BIA of this subgroup in three years ranges from 166.9 to 173.5 million euros.

Discussion

The emergence of high economic impact drugs makes economic studies necessary in order to favor the optimization of resources²¹. This economic evaluation compares two therapeutic alternatives in a group of patients diagnosed with eosinophilic asthma, showing signs that are consistent with the IgE-mediated persistent allergic asthma phenotype. The economic analysis design can help in clinical decision making to improve efficiency through price competition.

The health outcome was assessed by the number of avoided clinically relevant exacerbations with the use of mepolizumab. The selected variable is adequate to guide decision-making, as other studies assessed the decrease in hospital admissions, emergency room visits or primary care physicians²²⁻²⁴. On the other hand, the comparisons made regarding treatment alternatives (omalizumab and high dose of ICS + LABA and/or OCS) improve the validity of the study.

This study has limitations, such as the lack of effective comparative evidence and quality between mepolizumab and omalizumab in IgE-mediated eosinophilic asthma patients who are candidate population for both therapies, and specific intersection of the two sets, which lack empirical data. There have been two studies^{25,26} –one funded by GlaxoSmithKline laboratories– that performed an indirect comparison of mepolizumab against omalizumab in patients diagnosed with eosinophilic asthma and who show signs and symptoms that are consistent with the persistent allergic asthma phenoty-

pe. Although both describe no difference in efficacy between mepolizumab and omalizumab, they highlight the impossibility of making preferential use recommendations of one drug over another, due to its high heterogeneity between trials and different selection criteria for the use of both drugs. An indirect comparison analysis cannot be reliable, as mepolizumab was studied in eosinophilic component-mediated asthma, regardless of the IgE values, while omalizumab was studied in IgE-mediated asthma regardless of the eosinophilic component, and is used in patients with elevated IgE nonresponders to other treatments. These limitations were highlighted in reports evaluating mepolizumab in countries such as Canada²⁷ and the United Kingdom²⁸. Therefore, there has not been a cost minimization, but instead, it would be reasonable to select drugs by comparing costs, except for certain patients who, for any valid clinical reason, prefer one or avoid another.

Upon completion of the study, two other drugs with a similar mechanism of action to mepolizumab's were approved, although they were not yet sold in Spain, therefore, they were not the subject of this study^{14,15}. Once marketed, and considering that they have not been compared to mepolizumab, an assessment on whether the possible indirect comparisons detect clinically relevant differences should be performed, taking into account the level of eosinophils in plasma. Its introduction in therapy could allow competition and reduce the budgetary impact of these agents. Its non inclusion in this study is a limitation that should be addressed in subsequent studies, which should be focused on these similar treatments' potential competition once the first one –mepolizumab– is already marketed. Further comparison of these drugs in the same group would be appropriate, but also complex, because they have not been directly compared. These studies have different inclusion criteria and different subgroups definition, according to eosinophil count in blood.

Previous studies show that patients with elevated plasma eosinophil count benefit more patients, as opposed to low level patients^{8,9}. It was observed in this economic analysis that patients with \geq 500 eosinophils/ μ L showed a more favorable incremental cost-effectiveness compared to those with lower counts. It should be stressed that subgroup analysis on pivotal trials meets the pre-specification, interaction, consistency in different studies^{7,12} and biological plausibility criteria. The published economic evaluation studies on mepolizumab with refractory eosinophilic asthma population, regardless of subgroup analysis, concluded that mepolizumab is not cost-effective, urging price discounts around 60-70% to become funding-recommended by the healthcare systems^{29,30}. Bermejo *et al.*²⁸ described the assessment process on mepolizumab by the National Institute for Health and Care Excellence (NICE). In its economic assessment study, the target population was defined in terms of severity of asthma and \geq 300 eosinophils/ μ L levels. They have shown to not be cost-effective for this subgroup of patients, and its use was recommended only when the laboratory provides an agreed and confidential price discount, so that it becomes cost-effective for said subgroup of patients.

To conclude, comparative clinical evidence is lacking quality between mepolizumab and omalizumab in eosinophilic component-mediated asthma and IgE mediated patients. Nor are there other economic evaluation studies comparing these two drugs. For this reason, a cost comparison in these patients was performed. From Spanish NHS perspective, and considering the high economic impact of mepolizumab, it would be reasonable

to use the lower-cost drug and promote price competition. This strategy does not exclude the exceptional justified preference of a particular therapy by a patient. After this pharmacoeconomic analysis, prioritizing the use of mepolizumab in patients diagnosed with non IgE-mediated severe refractory eosinophilic asthma with high plasma levels of eosinophils (≥ 500 cells/ μL), as indicated in Therapeutic Positioning Report on mepolizumab by the Spanish Agency of Medicines, would significantly improve the efficiency and reduce its budgetary impact².

Funding

No funding.

Conference Presentations

Preliminary data as part of the work in the form of communication were presented under the name of: "Application of pharmacoeconomic evalua-

tion by subgroups to severe refractory eosinophilic asthma". 15th Andalusian Society of Hospital Pharmacy Congress, Almería, April 11-13, 2018.

Conflict of interests

No conflict of interest.

Contribution to the scientific literature

Study's contribution to existing knowledge: First published national data on mepolizumab's efficiency and budgetary impact for asthma patients.

Implications of the findings for practice, research, healthcare policies or general hospital pharmacy: Optimization of the use in the practice of mepolizumab by comparing costs and subgroup analysis.

Table 4. Mepolizumab budget impact analysis for non IgE-mediated severe eosinophilic asthma population and subgroups during 2018-2020 (subgroup analysis sensitivity ≥ 500 eosinophils/ μL)

Year	Population	MEPO cost (€)	Avoided exacerbations savings (€)	BIA (€)
Non IgE-mediated uncontrolled severe eosinophilic asthma				
2018	13,668	192,960,266.98	3,934,849.62	189,025,417.36
2019	13,692	193,300,104.59	3,941,779.60	189,358,325.00
2020	13,719	193,691,066.81	3,949,752.11	189,741,314.70
2018-2020		579,951,438.38	11,826,381.33	568,125,057.06
Subgroup: <150 eosinophils/μL				
2018	3,154	44,529,292.00	518,401.30	44,010,891.08
2019	3,160	44,607,716.00	519,314.30	44,088,402.14
2020	3,166	44,697,938.00	520,364.65	44,177,573.85
2018-2020		133,834,946.00	1,558,080.25	132,276,867.07
Subgroup: 150 to <300 eosinophils/μL				
2018	3,564	50,321,721.00	980,748.43	49,340,972.23
2019	3,571	50,410,346.00	982,475.70	49,427,870.53
2020	3,578	50,512,304.00	984,462.82	49,527,841.66
2018-2020		151,244,371.00	2,947,686.95	148,296,684.42
Subgroup: 300 to <500 eosinophils/μL				
2018	2,795	39,460,917.64	992,054.77	38,468,862.87
2019	2,800	39,530,415.39	993,801.96	38,536,613.43
2020	2,806	39,610,368.26	995,811.99	38,614,556.27
2018-2020		118,601,701.29	2,981,668.72	115,620,032.57
Subgroup: ≥ 500 eosinophils/μL				
2018	4,154	58,648,336.31	1,100,769.67	57,547,566.63
2019	4,161	58,751,626.54	1,102,708.32	57,648,918.21
2020	4,170	58,870,455.58	1,104,938.62	57,765,516.95
2018-2020		176,270,418.43	3,308,416.61	172,962,001.79
Subgroup: ≥ 500 eosinophils/μL (maximum RR values and minimum values in hospital and emergency care costs)				
2018	4,154	58,648,336.31	144,528.13	57,740,906.78
2019	4,161	58,751,626.54	144,782.67	57,842,598.87
2020	4,170	58,870,455.58	145,075.50	57,959,589.34
2018-2020		176,270,418.43	434,386.30	173,543,094.99
Subgroup: ≥ 500 eosinophils/μL (minimum RR values and maximum values in hospital and emergency care costs)				
2018	4,154	58,648,336.31	3,092,238.16	55,556,098.15
2019	4,161	58,751,626.54	3,097,684.14	55,653,942.39
2020	4,170	58,870,455.58	3,103,949.41	55,766,506.17
2018-2020		176,270,418.43	9,293,871.71	166,976,546.71

BIA: budget impact analysis; MEPO: mepolizumab; RR: relative risk.

Bibliography

- Spanish Group of the European Study on Asthma. Prevalence of bronchial hyperactivity and asthma in young adults from 5 Spanish areas. European study of asthma. *Med Clin (Barc)*. 1996;106(20):761-7.
- Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of Uncontrolled Severe Persistent Asthma in Pneumology and Allergy Hospital Units in Spain. *J Investig Allergol Clin Immunol*. 2011;21:6.
- Guía Española para el Manejo del Asma (GEMA 4.3) [Internet]. Madrid: Luzán. 2018 [accessed 12/05/2019]. Available at: <https://www.sem.ges/index.php/consensos-guias-y-protocolos/279-gema-4-3-guia-espanola-para-el-manejo-del-asma>
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, *et al*. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43(2):343-73. DOI: 10.1183/09031936.00202013.
- Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Xolair® 150 mg solución inyectable [internet] Madrid. Centro de información de medicamentos (CIMA) [accessed 12/05/2019]. Available at: https://cima.aemps.es/cima/dochtml/ft/05319008/FT_05319008.html
- Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Nucala® 100 mg polvo para solución inyectable [internet] Madrid. Centro de información de medicamentos (CIMA) [accessed 12/05/2019]. Available at: https://cima.aemps.es/cima/dochtml/ft/1151043001/FT_1151043001.html
- European Medicines Agency. Ficha técnica de Nucala® [Internet] [accessed 12/05/2019]. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/nucala>
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, *et al*. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012;380(9842):651-9. DOI: 10.1016/S0140-6736(12)60988-X
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, *et al*. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *N Engl J Med*. 2014;371(13):1198-207. DOI: 10.1056/NEJMx150017
- Tran TN, Khattry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. *Ann Allergy Asthma Immunol*. 2014;113(1):19-24. DOI: 10.1016/j.anaai.2014.04.011
- Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, *et al*. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med* [journal at Internet]. 2015 [accessed 12/05/2019]. Available at: [https://www.thelancet.com/journals/lanres/article/PIIS2213-2600\(15\)00367-7/fulltext](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(15)00367-7/fulltext). DOI: 10.1016/S2213-2600(15)00367-7
- Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terapéutico de mepolizumab (Nucala®) como tratamiento adicional en el asma eosinofílica refractoria grave [Internet]. Madrid; 2016 [accessed 12/05/2019]. Available at: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-mepolizumab-Nucala-asma_EPOC.pdf
- Omaliuzumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients - Full Text View - ClinicalTrials.gov [Internet]. 2016 [accessed 12/05/2019]. Available at: <https://clinicaltrials.gov/ct2/show/NCT02654145>
- Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Cinquero® 10 mg/ml concentrado para solución para perfusión Centro de información de medicamentos (CIMA) [web page]. Madrid [accessed 12/05/2019]. Available at: https://cima.aemps.es/cima/dochtml/ft/1161125001/FichaTecnica_1161125001.html
- Agencia Española de Medicamentos y Productos Sanitarios. Ficha técnica Fasentra® 30 mg solución inyectable en jeringa precargada. Centro de información de medicamentos (CIMA) [web page]. Madrid [accessed 12/05/2019]. Available at: https://cima.aemps.es/cima/dochtml/ft/1171252001/FT_1171252001.html
- López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, *et al*. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. *Gac Sanit*. 2010;24(2):154-70. DOI: 10.1016/j.gaceta.2009.07.011
- Sullivan SD, Mauskopf JA, Augustovski F, Caro J, Lee KM, Minchin M, *et al*. Budget Impact Analysis. Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force - Value in Health [journal at Internet]. 2014 [accessed 12/5/19];17(1):5-14. Available at: [https://www.valueinhealthjournal.com/article/S1098-3015\(13\)04235-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301513042356%3Fsho%3Druw](https://www.valueinhealthjournal.com/article/S1098-3015(13)04235-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301513042356%3Fsho%3Druw). DOI: <https://doi.org/10.1016/j.jval.2013.08.2291>
- Instituto Nacional de Estadística. España en cifras 2015 [monography at Internet]. 2015 [accessed 12/05/2019]. Available at: https://www.ine.es/prodyser/espa_cifras/2015/files/assets/basic-html/page2.html
- Consejo General de Colegios Oficiales de Farmacéuticos. BOT Plus 2. Base de Datos de Medicamentos [data base at Internet]. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2013 [2016; accessed 12/05/2019]. Available at: <https://botplusweb.portalfarma.com/botplus.aspx>
- Martínez-Moragón E, Serra-Ballés J, De Diego A, Palop M, Casan P, Rubio-Terrés C, *et al*. Coste económico del paciente asmático en España (estudio AsmaCost). *Arch Bronconeumol*. 2009;45(10):481-6. DOI: 10.1016/j.arbres.2009.04.006
- Moon JC, Flett AS, Godman BB, Grosso AM, Wierzbicki AS. Getting better value from the NHS drug budget. *BMJ*. 2010;341:c6449. DOI: 10.1136/bmj.c6449
- Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, *et al*. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy [journal at Internet]. 2005 [accessed 12/05/2019]; 60(3):309-16 Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1398-9995.2004.00772.x>
- Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, *et al*. Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations? Results From a Large Cohort of Patients With Severe Uncontrolled Asthma. *Chest*. 2013;143(2):398-405. DOI: 10.1378/chest.12-1372
- McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. *Pharmacoeconomics*. 2018;36(8):957-71. DOI: 10.1007/s40273-018-0658-x
- Cockle SM, Stynes G, Gunsoy NB, Parks D, Alfonso-Cristancho R, Wex J, *et al*. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. *Respir Med*. 2017;123:140-8. DOI: 10.1016/j.rmed.2016.12.009
- Nachef Z, Krishnan A, Mashtare T, Zhuang T, Mador MJ. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. *J Asthma*. 2018;55(1):89-100. DOI: 10.1080/02770903.2017.1306548
- Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Clinical Review Report for Nucala®. 2016 [accessed 08/03/2018]. Available at: https://www.cadth.ca/sites/default/files/cdr/clinical/SRO461_Nucala_CL_Report_e.pdf
- Bermejo I, Stevenson M, Cooper K, Harman S, Hamilton J, Clowes M, *et al*. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics* [journal at Internet]. 2017 [accessed 12/05/2019]. Available at: <http://eprints.whiterose.ac.uk/121723/9/Mepolizumab%20Pharmacoeconomics%20author%20version.pdf>. DOI: 10.1007/s40273-017-0571-8
- Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, *et al*. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. *Ann Allergy Asthma Immunol*. 2017;118(2):220-5. DOI: 10.1016/j.anaai.2016.10.028
- Tice JA, Ollendorf DA, Campbell JD, Chapman R, Shore KK, Weissberg J, *et al*. Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the treatment of severe asthma with eosinophilia: effectiveness, value, and value-based price benchmarks: final report. Institute for Clinical and Economic Review ICER 2016:1-88.